Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie Gets FDA Approval for Rinvoq for Ages 12 and Older

01/14/2022 | 01:49pm EST

By Chris Wack


AbbVie Inc. said the U.S. Food and Drug Administration has approved Rinvoq upadacitinib for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older.

The company said Rinvoq 15 mg once daily can now be initiated in adults and children 12 years of age and older weighing at least 40 kg. In those children and adults less than 65 years of age who don't achieve an adequate response, the dose may be increased to 30 mg once daily.

AbbVie said the FDA approval is supported by efficacy and safety data from one of the largest registrational Phase 3 programs for atopic dermatitis, with more than 2,500 patients evaluated across three studies. About 52% of the patients had prior exposure to systemic atopic dermatitis treatment.

These studies evaluated the efficacy and safety of Rinvoq monotherapy and with topical corticosteroids, compared to placebo, in adults and children 12 years of age and older with moderate to severe atopic dermatitis.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-14-22 1349ET

All news about ABBVIE INC.
01/18Cowen Adjusts AbbVie's Price Target to $150 From $130, Keeps Outperform Rating
MT
01/18I-Mab Doses First Patient in Mid-Stage Lemzoparlimab Combo Trial in Advanced Solid Tumo..
MT
01/17AbbVie - U.S. FDA Approves RINVOQ (upadacitinib) to Treat Adults and Children 12 Years ..
AQ
01/14U.S. FDA approves drugs from AbbVie, Pfizer to treat eczema
RE
01/14FDA approves expanded use of AbbVie's arthritis drug to treat eczema
RE
01/14AbbVie Gets FDA Approval for Rinvoq for Ages 12 and Older
DJ
01/14AbbVie Says FDA Approves Rinvoq to Treat Atopic Dermatitis
MT
01/14U.S. FDA Approves RINVOQ« (upadacitinib) to Treat Adults and Children 12 Years and Olde..
PR
01/14U.S. FDA Approves RINVOQ« (upadacitinib) to Treat Adults and Children 12 Years and Olde..
CI
01/13Redburn Initiates AbbVie With Buy Rating
MT
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 215 M - -
Net income 2021 11 140 M - -
Net Debt 2021 63 509 M - -
P/E ratio 2021 21,6x
Yield 2021 3,87%
Capitalization 239 B 239 B -
EV / Sales 2021 5,38x
EV / Sales 2022 4,86x
Nbr of Employees 50 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 135,21 $
Average target price 140,48 $
Spread / Average Target 3,90%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael CFO, Vice Chairman-Finance & Commercial Operations
Thomas J. Hudson VP, Head-Oncology Discovery & Early Development
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.-0.14%239 035
JOHNSON & JOHNSON-2.62%438 538
ROCHE HOLDING AG-3.53%323 214
PFIZER, INC.-9.33%300 513
NOVO NORDISK A/S-12.67%223 059
ELI LILLY AND COMPANY-11.28%222 160